 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
||||
|
||||
|
Abacavir and lamivudine, two medications that have been used for years to treat HIV infection, are available as EPZICOM. Take one EPZICOM Tablet once a day as part of your HIV combination regimen. EPZICOM has no food or fluid requirements.
Information contained within this Web site does not cover all possible uses, actions, warnings, precautions, side effects, or interactions of EPZICOM™ (which contains abacavir sulfate and lamivudine) with other medicines you may take. If you have questions about the information provided, ask your healthcare professional. More information, written in technical medical language for healthcare professionals, is available. You can request this information from your healthcare professional. EPZICOM, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults. EPZICOM is one of 3 medicines containing abacavir. Before starting EPZICOM, your healthcare professional will review your medical history in order to avoid the use of abacavir if you have experienced a hypersensitivity reaction to abacavir in the past. In one study, more patients had a severe hypersensitivity reaction in the abacavir once-daily group than in the abacavir twice-daily group. EPZICOM should not be used as part of a triple nucleoside regimen. EPZICOM does not cure HIV infection/AIDS or prevent passing HIV to others. |
|
 |
|
|
|
You are encouraged to report negative side effects of prescription drugs to the FDA. 
This site is intended for US residents only. © 1997-2008 GlaxoSmithKline. All Rights Reserved. |
